Absci (NASDAQ:ABSI – Get Rating) and DNAPrint Genomics (OTCMKTS:DNAG – Get Rating) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.
Volatility and Risk
Absci has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Comparatively, DNAPrint Genomics has a beta of -0.67, meaning that its share price is 167% less volatile than the S&P 500.
Institutional and Insider Ownership
47.6% of Absci shares are owned by institutional investors. 19.4% of Absci shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current recommendations for Absci and DNAPrint Genomics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Absci presently has a consensus target price of $9.00, suggesting a potential upside of 426.32%.
Earnings & Valuation
This table compares Absci and DNAPrint Genomics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Absci||$6.20 million||25.52||-$104.90 million||($1.09)||-1.57|
DNAPrint Genomics has lower revenue, but higher earnings than Absci.
Absci beats DNAPrint Genomics on 5 of the 8 factors compared between the two stocks.
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
About DNAPrint Genomics
DNAPrint Genomics, Inc. engages in the research and development of genomics-based products and services for biomedical and forensics. The company was founded by Tony N. Frudakis on January 3, 1983 and is headquartered in Sarasota, FL.
Receive News & Ratings for Absci Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Absci and related companies with MarketBeat.com's FREE daily email newsletter.